Recordati: Leveraging an In-House Success to Boost In-Licensing
Executive Summary
In-licensor Recordati is confident that the supply of products won't dry up; it will just come from different players. Meanwhile, the 76-year old family-owned Italian drug company will leverage US sales of lercanidipine, its in-house jewel, to fuel expansion outside an increasingly price-constrained domestic market.